Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 10/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29649168 | 0.95 | ACE (0.46) | ACE | |
| SCHEMBL5322318 | 0.77 | ALDH1A1 (0.58) | ACE | |
| SCHEMBL19753551 | 0.74 | SMN1; SMN2 (0.50) | ACE | |
| SCHEMBL15384058 | 0.74 | SMN1; SMN2 (0.50) | ACE | |
| SCHEMBL5130749 | 0.72 | SMN1; SMN2 (0.53) | ACE | |
| SCHEMBL5130748 | 0.72 | SMN1; SMN2 (0.53) | ACE | |
| SCHEMBL26724731 | 0.70 | CA1 (0.38) | — | |
| SCHEMBL4739541 | 0.69 | ACE (0.49) | ACE | |
| SCHEMBL4739536 | 0.69 | ACE (0.49) | ACE | |
| SCHEMBL9515265 | 0.68 | ACE (0.53) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388940-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | CODEXIS, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-12421532-B2 | Polynucleotides encoding engineered imine reductases | CODEXIS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20230295673-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2023-09-21 | — | — | US | disclosed |
| US-11618911-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-20220315961-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2022-10-06 | — | — | US | disclosed |
| US-11377673-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388940-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | DCXR, PDXK, XDH | ACE 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.